Literature DB >> 8995670

Mutations in the matrix protein of human immunodeficiency virus type 1 inhibit surface expression and virion incorporation of viral envelope glycoproteins in CD4+ T lymphocytes.

Y M Lee1, X B Tang, L M Cimakasky, J E Hildreth, X F Yu.   

Abstract

Highly conserved amino acids in the second helix structure of the human immunodeficiency virus type 1 (HIV-1) MA protein were identified to be critical for the incorporation of viral Env proteins into HIV-1 virions from transfected COS-7 cells. The effects of these MA mutations on viral replication in the HIV-1 natural target cells, CD4+ T lymphocytes, were evaluated by using a newly developed system. In CD4+ T lymphocytes, mutations in the MA domain of HIV-1 Gag also inhibited the incorporation of viral Env proteins into mature HIV-1 virions. Furthermore, mutations in the MA domain of HIV-1 Gag reduced surface expression of viral Env proteins in CD4+ T lymphocytes. The synthesis of gp160 and cleavage of gp160 to gp120 were not significantly affected by MA mutations. On the other hand, the stability of gp120 in MA mutant-infected cells was significantly reduced compared to that in the parental wild-type virus-infected cells. These results suggest that functional interaction between HIV-1 Gag and Env proteins is not only critical for efficient incorporation of Env proteins into mature virions but also important for proper intracellular transport and stable surface expression of viral Env proteins in infected CD4+ T lymphocytes. A single amino acid substitution in MA abolished virus infectivity in dividing CD4+ T lymphocytes without significantly affecting virus assembly, virus release, or incorporation of Gag-Pol and Env proteins, suggesting that in addition to its functional role in virus assembly, the MA protein of HIV-1 also plays an important role in other steps of virus replication.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8995670      PMCID: PMC191201     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Human immunodeficiency virus envelope protein determines the site of virus release in polarized epithelial cells.

Authors:  R J Owens; J W Dubay; E Hunter; R W Compans
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

2.  The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions.

Authors:  X Yu; X Yuan; Z Matsuda; T H Lee; M Essex
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

3.  Retained in vitro infectivity and cytopathogenicity of HIV-1 despite truncation of the C-terminal tail of the env gene product.

Authors:  T Wilk; T Pfeiffer; V Bosch
Journal:  Virology       Date:  1992-07       Impact factor: 3.616

4.  Effects of deletions in the cytoplasmic domain on biological functions of human immunodeficiency virus type 1 envelope glycoproteins.

Authors:  D H Gabuzda; A Lever; E Terwilliger; J Sodroski
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

Review 5.  The budding mechanisms of enveloped animal viruses.

Authors:  K Simons; H Garoff
Journal:  J Gen Virol       Date:  1980-09       Impact factor: 3.891

6.  Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160.

Authors:  R L Willey; J S Bonifacino; B J Potts; M A Martin; R D Klausner
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

7.  Assembly and release of SIV env proteins with full-length or truncated cytoplasmic domains.

Authors:  A N Vzorov; R W Compans
Journal:  Virology       Date:  1996-07-01       Impact factor: 3.616

8.  Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity.

Authors:  J W Dubay; S J Roberts; B H Hahn; E Hunter
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 envelope protein endocytosis mediated by a highly conserved intrinsic internalization signal in the cytoplasmic domain of gp41 is suppressed in the presence of the Pr55gag precursor protein.

Authors:  M A Egan; L M Carruth; J F Rowell; X Yu; R F Siliciano
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

10.  The C terminus of human immunodeficiency virus type 1 matrix protein is involved in early steps of the virus life cycle.

Authors:  X Yu; Q C Yu; T H Lee; M Essex
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

View more
  31 in total

1.  The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions.

Authors:  T Murakami; E O Freed
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  RNA dimerization defect in a Rous sarcoma virus matrix mutant.

Authors:  L J Parent; T M Cairns; J A Albert; C B Wilson; J W Wills; R C Craven
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  HIV-1 Matrix Trimerization-Impaired Mutants Are Rescued by Matrix Substitutions That Enhance Envelope Glycoprotein Incorporation.

Authors:  Philip R Tedbury; Mariia Novikova; Ayna Alfadhli; Yuta Hikichi; Ioannis Kagiampakis; Vineet N KewalRamani; Eric Barklis; Eric O Freed
Journal:  J Virol       Date:  2019-12-12       Impact factor: 5.103

4.  The putative alpha helix 2 of human immunodeficiency virus type 1 Vpr contains a determinant which is responsible for the nuclear translocation of proviral DNA in growth-arrested cells.

Authors:  Z Nie; D Bergeron; R A Subbramanian; X J Yao; F Checroune; N Rougeau; E A Cohen
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

5.  Multiple Gag domains contribute to selective recruitment of murine leukemia virus (MLV) Env to MLV virions.

Authors:  Devon A Gregory; Terri D Lyddon; Marc C Johnson
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

6.  Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.

Authors:  Tao Zuo; Donglai Liu; Wei Lv; Xiaodan Wang; Jiawen Wang; Mingyu Lv; Wenlin Huang; Jiaxin Wu; Haihong Zhang; Hongwei Jin; Liangren Zhang; Wei Kong; Xianghui Yu
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

7.  Comparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitors.

Authors:  R R Speck; C Flexner; C J Tian; X F Yu
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

8.  Elucidating the Basis for Permissivity of the MT-4 T-Cell Line to Replication of an HIV-1 Mutant Lacking the gp41 Cytoplasmic Tail.

Authors:  Melissa V Fernandez; Huxley K Hoffman; Nairi Pezeshkian; Philip R Tedbury; Schuyler B van Engelenburg; Eric O Freed
Journal:  J Virol       Date:  2020-11-09       Impact factor: 5.103

9.  Multiple functions for the basic amino acids of the human T-cell leukemia virus type 1 matrix protein in viral transmission.

Authors:  I Le Blanc; A R Rosenberg; M C Dokhélar
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 protease triggers a myristoyl switch that modulates membrane binding of Pr55(gag) and p17MA.

Authors:  L Hermida-Matsumoto; M D Resh
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.